Skip to main content

A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Behavioral Neurology

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2016

End Date

November 20, 2020
 

Administered By

Neurology, Behavioral Neurology

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2016

End Date

November 20, 2020